Improved Tumor Targeting with Anti-Tumor Antibody Fragments
Author Information
Author(s): JL Casey, DJ King, LC Chaplin, AMR Haines, RB Pedley, A Mountain, GT Yarranton, RHJ Begent
Primary Institution: Cancer Research Campaign Laboratories, Department of Clinical Oncology, Royal Free Hospital School of Medicine
Hypothesis
Which form of the A5B7 antibody is optimal for radioimmunotherapy with isotopes 131I and 90Y?
Conclusion
The study concludes that 90Y-labelled A5B7 TFM is the most suitable antibody species for radioimmunotherapy.
Supporting Evidence
- DFM had the fastest association rate among the antibody forms tested.
- Both DFM and TFM showed favorable properties compared to their parent antibody forms.
- 90Y-labelled antibodies had higher tumor uptake than 131I-labelled antibodies.
- TFM cleared from the blood significantly faster than A5B7 IgG when labelled with both isotopes.
Takeaway
Researchers tested different forms of an antibody to see which one works best for treating tumors with radiation. They found that a specific version of the antibody is better at targeting tumors while causing less harm to the kidneys.
Methodology
The study compared the biodistribution of different antibody fragments in nude mice with human colorectal tumor xenografts.
Limitations
The study used a mouse model, which may not fully represent human responses.
Participant Demographics
Nude mice bearing human colorectal tumor xenografts.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.02
Want to read the original?
Access the complete publication on the publisher's website